You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 5,750,390


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,750,390
Title: Method and reagent for treatment of diseases caused by expression of the bcl-2 gene
Abstract:An enzymatic RNA molecule which cleaves bcl.2 mRNA associated with development or maintenance of follicular lymphoma.
Inventor(s): Thompson; James D. (Boulder, CO), Draper; Kenneth G. (Boulder, CO)
Assignee: Ribozyme Pharmaceuticals, Inc. (Boulder, CO)
Application Number:07/936,421
Patent Claims:1. The enzymatic RNA molecule which specifically cleaves bcl-2 RNA.

2. The enzymatic RNA molecule of claim 1 which specifically cleaves the sequence shown as any of SEQ. ID. NOS. 1-22, wherein said enzymatic RNA molecule is in the hepatitis delta virus motif.

3. The enzymatic RNA molecule of claim 1 wherein said enzymatic RNA molecule is in a hammerhead motif.

4. The enzymatic RNA molecule of claim 1 wherein said enzymatic RNA molecule is in a hairpin, hepatitis delta virus, group I intron or RNase P RNA motif.

5. The enzymatic RNA molecule of claim 1 wherein said enzymatic RNA molecule comprises between 5 and 23 bases complementary to said RNA.

6. The enzymatic RNA molecule of claim 1 wherein said enzymatic RNA molecule comprises between 10 and 18 bases complementary to said RNA.

7. The enzymatic RNA molecule of claim 1 which specifically cleaves the sequence shown as any of SEQ. ID. NOS. 1-22, wherein said enzymatic RNA molecule is in the hammerhead motif.

8. The enzymatic RNA molecule of claim 1, wherein the enzymatic RNA molecule comprises an 2'-O-methyl modification in at least one sugar moiety.

9. The enzymatic RNA molecule of claim 1, wherein said enzymatic RNA molecule comprises at least one phosphorothioate group.

10. A vector comprising a nucleic acid encoding the enzymatic RNA molecule of claim 1 operatively linked to a promoter.

11. A mammalian cell in vitro comprised of an enzymatic RNA molecule of any one of claims 1-7.

12. The cell of claim 11, wherein the cell is a human cell.

13. A mammalian cell in vitro comprising a vector of claim 10.

Details for Patent 5,750,390

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2039-02-26
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2039-02-26
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2039-02-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.